
1) Validate surrogate endpoints that predict long-term outcomes 2) Allow accelerated approval through a modified 505(b)(2) pathway for approved drugs with all-cause mortality benefits across multiple diseases

We’re developing the first drugs intended to help dogs live longer, healthier lives 🐕

1) Validate surrogate endpoints that predict long-term outcomes 2) Allow accelerated approval through a modified 505(b)(2) pathway for approved drugs with all-cause mortality benefits across multiple diseases

New in GeroScience: Lessons from dog lifespan therapeutics for their human companions. Our research team proposes two strategies to help overcome the barriers to human longevity drug development, modeled on the conditional approval framework the FDA already uses in veterinary medicine and that we’re using for dog lifespan extension drugs: hubs.la/Q04Ctv520

We're getting closer to the first longevity drugs for dogs. Hear about our latest progress from the team making it happen → hubs.la/Q04xXVds0

Hear from our chief scientist on what this milestone means for LOY-003 and our strategy for developing the first longevity drugs for dogs → loyal.com/LOY-003-RXE

LOY-003, our pill for large- and giant-breed dog lifespan extension, completed the efficacy section (RXE) of its conditional approval application.

After 5 years, I am still excited to be a part of this team and this work!
When we started Loyal there was no FDA pathway for a any lifespan extension drug. Today the FDA accepted our third one! LOY-003, our daily pill for helping large dogs live longer (and healthier) lives, has earned RXE efficacy approval.

Congrats to the Loyal team! 🐶 @celinehalioua has been talking about this drug since the earliest days of Loyal. Very exciting!
When we started Loyal there was no FDA pathway for a any lifespan extension drug. Today the FDA accepted our third one! LOY-003, our daily pill for helping large dogs live longer (and healthier) lives, has earned RXE efficacy approval.

Learn more about our latest regulatory progress → loyal.com/LOY-003-RXE

We’re one step closer to the first FDA-approved longevity drugs for dogs 🐶🎉 Now, all three drugs currently in our portfolio have met the FDA’s efficacy requirements for conditional approval, a first for any pharma company.
When we started Loyal there was no FDA pathway for a any lifespan extension drug. Today the FDA accepted our third one! LOY-003, our daily pill for helping large dogs live longer (and healthier) lives, has earned RXE efficacy approval.

Pick a topic: What are you most interested in learning about?

Every dog ages differently: Which sign of aging stands out in your dog or patients?

For the dog owners: how much does your dog weigh?

Four quick polls from the Loyal team: Are you a dog owner or veterinary professional?

Congratulations to Reel as Dirt, Cityspeak Films, and everyone who brought it to the screen. Learn more about the film or find tickets to see it in person: theawordfilm.com/

The A-Word: The Future of Aging premieres tonight at the 25th @Tribeca Film Festival. An independent documentary about growing old well and the founders and scientists working to add life to years. It's honest, hopeful, and our founder @celinehalioua is one of the voices in it.

"If we pull this off, my team will be responsible for potentially millions of dog years that wouldn't have otherwise existed." Learn more about our journey in @BainCapVC 's latest Outlier Briefing with @kevinzhang and @celinehalioua → youtu.be/LXqF5tohXt8
This startup wants dogs to live longer. If that’s not enough to get you to watch, we’re not sure what will. But if you need more convincing, @celinehalioua built @loyalfordogs after years of doubt and is now running the first ever FDA-concurred lifespan extension clinical trial. Featuring 1,300 really good boys and girls. And yes, everyone will get a pup cup after. Full Outlier Briefing with @kevinzhang out now.